Senores Pharmaceuticals
MAINBOARD
Listed
Price Band
₹372 - ₹391
Lot Size
38 Shares
Issue Size
₹82.11 Cr
Fresh Issue
Nil (Pure OFS)
OFS
₹82.11 Cr (Full Issue)
Registrar
Link Intime India Private Limited
AI Sentiment Score
Listing Price
₹600.00
vs Issue: ₹391 (+53.45%)
📅 IPO Timeline
✓
Open
Dec 20, 2024
✓
Close
Dec 24, 2024
✓
Allotment
Dec 25, 2024
✓
Refund
Dec 26, 2024
✓
Demat
Dec 26, 2024
✓
Listing
Dec 30, 2024
📈 Grey Market Premium (GMP) Trendline
Daily consensus GMP movement (₹) recorded across market sources
✨ AI Analysis & Prediction
+18.5%
predicted listing gain
Senores Pharmaceuticals displays an established operational footprint with expanding revenue streams (162.5% CAGR) and a defensible value proposition.
💪 Strengths
- Demonstrated operational revenue trajectory with resilient top-line growth (162.5% CAGR).
- Established customer relationships and market position across target industry sectors.
- Sound operational capital returns with Return on Capital Employed (ROCE) at 15.1%.
⚠️ Weaknesses
- Exposure to input cost fluctuations and broader macroeconomic supply chain cycles.
- Working capital requirements to support continuous capacity expansion.
- Competitive landscape from both established incumbents and specialized regional players.
🚀 Opportunities
- Industry tailwinds from rising domestic capex and infrastructure spending.
- Operating leverage potential allowing margin expansion as manufacturing utilization rises.
- Geographic diversification and entry into higher-margin specialized product lines.
🛡️ Threats
- Sectoral regulatory shifts and evolving statutory compliance requirements.
- Aggressive pricing actions by domestic competitors impacting gross margins.
- Broader market equity volatility and liquidity fluctuations.
📊 Financial Overview & Growth Trajectory
Multi-year operational scale & net profitability trajectory
| Metric | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue (₹ Cr) | Rs 35.00 Cr | Rs 215.00 Cr | Rs 398.00 Cr | Rs 633.00 Cr |
| Net Profit / PAT (₹ Cr) | Rs 8.00 Cr | Rs 33.00 Cr | Rs 58.00 Cr | Rs 122.00 Cr |
| EBITDA / Op. Profit (₹ Cr) | Rs 13.00 Cr | Rs 42.00 Cr | Rs 90.00 Cr | Rs 168.00 Cr |
| Borrowings (₹ Cr) | Rs 63.00 Cr | Rs 258.00 Cr | Rs 315.00 Cr | Rs 342.00 Cr |
| Total Assets (₹ Cr) | Rs 131.00 Cr | Rs 622.00 Cr | Rs 1,227.00 Cr | Rs 1,604.00 Cr |
| ROE % | 0.00% | 0.00% | 0.00% | 0.00% |
| ROCE % | 15.10% | 15.10% | 15.10% | 15.10% |
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 |
Company P/E
50.6x
Industry P/E
58.2x
Debt/Equity
0.37
⚖️ Valuation Benchmark Range
🟢 Attractively Priced vs Industry Peers
Industry 58.2x
IPO 50.6x
0x (Deep Value)
79x (High Multiple)
📋 Live Subscription Status
QIB
94.66x
NII
101.83x
Retail
90.46x
Total
93.69x
🎯 Retail Allotment Probability
1.1% Odds
1 in 90.5 chance (~1.1% probability per PAN)
SEBI Rule: Under SEBI lottery allotment rules, applying for multiple lots under Retail does NOT increase your lottery odds. All valid retail applicants have identical 1-lot odds per PAN.
Updated: Sep 12, 2026 2:40 PM
💼 Issue Structure & Reservation Quota
Capital Structure
₹82.1 Cr
Issue Size
OFS (100%)
Reservation Quota
100%
Allocation
QIB (50%)
NII (15%)
Retail (35%)
QIB
50.00%
Retail
35.00%
NII
15.00%
Employee
0.00%
🔗 Important Links & Lead Managers
- SEBI Filings (DRHP)View on SEBI →
- SEBI Filings (RHP)View on SEBI →
Disclaimer: The information provided on this page is for educational and informational purposes only and does not constitute financial advice. IPO investments are subject to market risks. AI-generated analysis is based on publicly available data and may not be accurate. Grey Market Premium (GMP) is unofficial and highly speculative. Always consult a qualified financial advisor and read the DRHP/RHP carefully before making investment decisions.